Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

22 participants

Study Classification

OBSERVATIONAL

Study Start Date

2004-03-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The hypothesis of this study is that pegylated interferon would cause cognitive deficits and mood changes in hepatitis C (HCV) positive subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C

NCT00227149

Hepatitis C, Chronic

COMPLETED

Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)

NCT00788918

Hepatitis C, Chronic Cognition Disorders Fatigue Syndrome, Chronic +1 more

COMPLETED NA

Brain Deficits in HIV/HCV Coinfected People Before and After Anti-HCV Therapy

NCT00747539

HIV Hepatitis C Infections

COMPLETED

Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC)

NCT02745132

Hepatitis C

UNKNOWN PHASE4

Treatment of Hepatitis C in Psychiatric Patients

NCT00751426

Mental Disorders Drug Addiction

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects with non-cirrhotic hepatitis C will have a magnetic resonance imaging (MRI)/magnetic resonance (MR) spectroscopy and neuropsychological testing prior to starting interferon. Subjects will have repeat testing following 12 weeks of interferon therapy and again at 12 weeks post interferon therapy.

MR spectroscopy (MRS) will measure the cerebral metabolites, NAA (N-acetyl aspartate), Cho (choline), MI (myoinositol) and Cr (creatine) at 3 distinct brain regions, i.e. basal ganglia and 2 locations within the frontal cortex.

Neuropsychological testing will include tests of the following cognitive domains: executive functioning, memory, language, motor skills and will also include questionnaires pertaining to quality of life (SF-36), mood (Beck's depression inventory) and a self-rating cognitive questionnaire (Conners' Adult Attention Deficit Hyperactivity Disorder Rating Scales \[CAARS\]).

Control subjects will include non-cirrhotic HCV subjects who are not taking interferon therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Interferon Treated Group

Group treated with PEG-Interferon and ribavirin and undergoing MR brain and neuropsychiatric tests

MR brain and neuropsychiatric tests

Intervention Type DIAGNOSTIC_TEST

Non-treated cohort control

Group undergoing MR brain and neuropsychiatric tests

MR brain and neuropsychiatric tests

Intervention Type DIAGNOSTIC_TEST

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MR brain and neuropsychiatric tests

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults (\>18 years old) of both sexes with chronic HCV infection (all genotypes).
* Subjects due to start treatment with pegylated interferon-alpha (IFN-a) for HCV eradication.
* Subjects with chronic hepatitis C who have elected not to be treated with pegylated-IFN-a
* Subjects with mild fibrosis on liver biopsy (stage 0-III/IV fibrosis)
* Subjects able to give informed consent.
* Subjects with controlled depression currently taking anti-depressant medication.

Exclusion Criteria

* Subjects with cirrhosis on liver biopsy.
* Subjects with active alcohol or drug abuse.
* Subjects co-infected with human immunodeficiency virus (HIV).
* Subjects with structural brain abnormality, past history of cerebrovascular accident (CVA) or serious head trauma.
* Subjects with seizure disorder.
* Subjects with any contraindication to IFN therapy.
* Subjects with a poor command of the English language.
* Subjects with a contraindication to MRI, e.g. pacemaker, claustrophobia.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No